Will the PanSeer early cancer detection test be authorized for clinical use by 2022?

Early detection of tumors is essential to improve the patient's odds of successful treatment. With that in mind, researchers at Fudan University (China) were able to develop a new type of blood test capable of detecting cancers up to four years before symptoms appear.

The test, which was called PanSeer, uses artificial intelligence to detect changes in the DNA that are present in people with some types of cancer. This is not the same as predicting cancer, but a diagnosis, as the test detects cancerous growths that have not yet caused symptoms, and cannot yet be detected by other methods. Another advantage of the test is that it is non-invasive, as it does not require surgery to extract a tissue sample.

In its first tests, PanSeer was able to identify, with 95% accuracy, the presence of cancer in participants who had not yet been diagnosed, but who later developed the disease. However, further clinical trials are still needed to confirm the effectiveness of the method.

If PanSeer be authorized for clinical-diagnostic use by the end of 2020 by either the health surveillance agency of China (SFDA), Europe (EMA), or the United States (FDA), this market will be resolved as "Yes".